Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
As a traditional Chinese medicine compound, Yangxue Qingnao Pills is proven to have
beneficial effects on learning and memory ability in animal models of Alzheimer's
disease(AD). The purpose of the study is to evaluate the efficacy and safety of Yangxue
Qingnao Pills on patients with mild to moderate AD. This phase II randomized, double-blind,
parallel controlled trial include a 2 weeks run-in period, and a 48 weeks double-blind
treatment period of after randomization. Participants will be randomly allocated to Yangxue
Qingnao pills high dose group (7.5 g per time,2 times per day) ; and Yangxue Qingnao pills
low dose group (5 g per time,2 times per day), or placebo group. The outcome measures include
general cognitive function, ability of daily living, and behavioural and psychological
symptoms in AD patients.